Prognostic factors of restrictive myopathy in thyroid eye disease

被引:0
|
作者
Jae Hwan Choi
Hoon Noh
Yoon-Duck Kim
Kyung In Woo
机构
[1] Samsung Medical Center,Department of Ophthalmology
[2] Sungkyunkwan University School of Medicine,undefined
[3] Nune Eye Hospital,undefined
来源
Scientific Reports | / 11卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
To investigate the prognostic factors of extraocular muscle restriction in patients with thyroid eye disease (TED), 65 patients with TED and restrictive myopathy were evaluated. Demographics, clinical activity score (CAS), smoking status, thyroid disease status, thyroid hormone status, thyroid autoantibody status, orbital computed tomography (CT) scan at initial presentation, and treatment regimens were assessed. The movements of the most severely affected extraocular muscles were categorized into five grades. The patients were divided into the improved and the not-improved group based on the improvement in the limitation of the extraocular muscle excursion (LOM) throughout the follow-up, and the groups were compared using clinical factors. The mean LOM significantly improved from 2.3 ± 1.1 to 1.7 ± 1.2 after 1 year of follow-up. The excursion of the most restricted muscle improved in 32 patients but not in 33 patients during the follow-up. The initial concentration of the thyroid-stimulating antibody (TSAb) was significantly lower in the improved (229.3 ± 114.1) than in the not-improved group (345.0 ± 178.6) (P = 0.02) Age, sex, smoking status, CAS, thyroid status, and muscle thickness on the CT scan did not significantly differ in the groups. This study showed that the initial concentration of TSAb is a factor affecting the recovery of restrictive myopathy.
引用
收藏
相关论文
共 50 条
  • [41] Recurrent Thyroid Eye Disease
    Patel, Payal
    Khandji, Joyce
    Kazim, Michael
    OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2015, 31 (06): : 445 - 448
  • [42] Management of thyroid eye disease
    Bartalena, L
    Marcocci, C
    Tanda, ML
    Pinchera, A
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2002, 29 (Suppl 2) : S458 - S465
  • [43] An overview of thyroid eye disease
    Colm McAlinden
    Eye and Vision, 1
  • [44] Thyroid eye disease and glaucoma
    Goldberg, I
    JOURNAL OF GLAUCOMA, 2003, 12 (06) : 494 - 496
  • [45] Steroids in thyroid eye disease
    Leibovitch, Igal
    Kakizaki, Hirohiko
    Selva, Dinesh
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2010, 38 (07): : 657 - 658
  • [46] Noninflammatory Thyroid Eye Disease
    Ugradar, Shoaib
    Rootman, Daniel B.
    OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2019, 35 (05): : 461 - 464
  • [47] Asymmetrical thyroid eye disease
    Rana, Khizar
    Yong, Lee Shien S.
    Garg, Devanshu
    Leyden, James
    Patel, Sandy
    Slattery, James
    Davis, Garry
    Chan, WengOnn
    Selva, Dinesh
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2023, 51 (09): : 1003 - 1003
  • [48] Glycosaminoglycans in thyroid eye disease
    Kahaly, G
    Forster, G
    Hansen, C
    THYROID, 1998, 8 (05) : 429 - 432
  • [49] Rituximab for Thyroid Eye Disease
    Silkiss, Rona Z.
    Reier, Alice
    Coleman, Morton
    Lauer, Simeon A.
    OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2010, 26 (05): : 310 - 314
  • [50] An overview of thyroid eye disease
    McAlinden, Colm
    EYE AND VISION, 2014, 1